Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Immunological Reviews

• Publication date

  1995-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1600-065X.1995.tb00084.xPMID 7590828
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structure, chromosomal localization, and expression of 12 genes of the MAGE family

  2005cited by this paper
• Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes

  2004cited by this paper
• Sequence and expression pattern of the human MAGE2 gene

  2004cited by this paper
• CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma

  1997cited by this paper
• Expression of mage genes in transitional‐cell carcinomas of the urinary bladder

  1995cited by this paper
• BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes.

  1995cited by this paper
• Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1

  1995cited by this paper
• A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.

  1995cited by this paper
• Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection

  1995cited by this paper
• A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma

  1995cited by this paper
• Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815

  1995cited by this paper
• A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3

  1994cited by this paper
• Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes

  1994cited by this paper
• Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy.

  1994cited by this paper
• Structure of peptides associated with class I and class II MHC molecules.

  1994cited by this paper
• Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

  1994cited by this paper
• Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68.

  1994cited by this paper
• Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

  1994cited by this paper
• Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes.

  1994cited by this paper
• Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

  1994cited by this paper
• A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

  1994cited by this paper
• Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes

  1994cited by this paper
• CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma

  1994cited by this paper
• Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.

  1994cited by this paper
• Expression of mage genes by non‐small‐cell lung carcinomas

  1994cited by this paper
• An intracisternal A‐particle sequence codes for an antigen recognized by syngeneic cytolytic T lymphocytes on a mouse spontaneous leukemia

  1994cited by this paper
• Autologous cytolytic T lymphocytes recognize a MAGE‐1 nonapeptide on melanomas expressing HLA‐Cw* 1601

  1994cited by this paper
• Localization of two cytotoxic T lymphocyte epitopes and three anchoring residues on a single nonameric peptide that binds to H‐2Ld and is recognized by cytotoxic T lymphocytes against mouse tumor P815

  1994cited by this paper
• Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.

  1993cited by this paper
• Lysis of human pancreatic adenocarcinoma cells by autologous hla‐class I‐restricted cytolytic T‐lymphocyte (CTL) clones

  1993cited by this paper
• Melanoma cells and normal melanocytes share antigens recognized by HLA- A2-restricted cytotoxic T cell clones from melanoma patients

  1993cited by this paper
• Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules.

  1993cited by this paper
• The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas.

  1993cited by this paper
• Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma.

  1993cited by this paper
• In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53

  1993cited by this paper
• Analysis of antigens recognized on human melanoma cells by A2‐restricted cytolytic t lymphocytes (CTL)

  1993cited by this paper
• The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

  1993cited by this paper
• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

  1993cited by this paper
• A tumour‐associated antigen expression in human haematological malignancies

  1993cited by this paper
• Recognition of shared melanoma antigen by HLA‐A2‐restricted cytolytic T cell clones derived from human tumor‐infiltrating lymphocytes

  1993cited by this paper
• Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines.

  1993cited by this paper
• Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.

  1992cited by this paper
• An analysis of autologous T‐cell anti‐tumour responses in colon‐carcinoma patients following active specific immunization (ASI)

  1992cited by this paper
• Identification of tumour rejection antigens recognized by T lymphocytes.

  1992cited by this paper
• Toward a genetic analysis of tumor rejection antigens.

  1992cited by this paper
• In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium.

  1992cited by this paper
• Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells

  1992cited by this paper
• Mouse tumor rejection antigens P815A and P815B : Two epitopes carried by a single peptide

  1992cited by this paper
• Molecular analysis of the association of HLA-B53 and resistance to severe malaria

  1992cited by this paper
• Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors.

  1992cited by this paper
• A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E

  1992cited by this paper
• Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins.

  1992cited by this paper
• Common Expression of Melanoma Tumor-Associated Antigens Recognized by Human Tumor Infiltrating Lymphocytes: Analysis by Human Lymphocyte Antigen Restriction

  1991cited by this paper
• A novel brain-specific mRNA encoding nuclear protein (necdin) expressed in neurally differentiated embryonal carcinoma cells.

  1991cited by this paper
• The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice

  1991cited by this paper
• A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

  1991cited by this paper
• Efficacy studies on a canarypox-rabies recombinant virus.

  1991cited by this paper
• The binding affinity and dissociation rates of peptides for class I major histocompatibility complex molecules

  1991cited by this paper
• Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity.

  1990cited by this paper
• Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide

  1990cited by this paper
• Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas.

  1990cited by this paper
• Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells.

  1989cited by this paper
• Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens

  1989cited by this paper
• Presence on a human melanoma of multiple antigens recognized by autologous CTL

  1989cited by this paper
• Distribution of human leukocyte antigen-ABC and -D/DR antigens in the unfixed human testis.

  1988cited by this paper
• Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation.

  1988cited by this paper
• Allele and locus‐specific differences in cell surface expression and the association of HLA class I heavy chain with β2‐microglobulin: differential effects of inhibition of glycosylation on class I subunit association

  1988cited by this paper
• Proliferative and cytolytic potentials of purified human tumor‐infiltrating t lymphocytes. Impaired response to mitogen‐driven stimulation despite T‐cell receptor expression

  1988cited by this paper
• Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure.

  1987cited by this paper
• Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors.

  1987cited by this paper
• Production of stable cytolytic T‐cell clones directed against autologous human melanoma

  1987cited by this paper
• Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity.

  1986cited by this paper
• A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes.

  1986cited by this paper
• Clonal analysis of cytotoxic T‐lymphocyte response to autologous human metastatic melanoma

  1985cited by this paper
• T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures.

  1984cited by this paper
• Construction and applications of a highly transmissible murine retrovirus shuttle vector.

  1984cited by this paper
• Clonal analysis of cytotoxic T cell response against human melanoma

  1983cited by this paper
• A transmissible retrovirus expressing human hypoxanthine phosphoribosyltransferase (HPRT): gene transfer into cells obtained from humans deficient in HPRT.

  1983cited by this paper
• Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression

  1983cited by this paper
• Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis

  1983cited by this paper
• Specificity of auto‐tumor cytotoxicity exerted by fresh, activated and propagated human t lymphocytes

  1982cited by this paper
• Specific cytotoxicity against autologous tumour and proliferative responses of human lymphocytes grown in interleukin 2

  1982cited by this paper
• Cell‐mediated cytotoxicity for cultured autologous melanoma cells

  1979cited by this paper
• TUMOR INFILTRATING LYMPHOCYTES *

  1976cited by this paper
• A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin.

  1976cited by this paper
• Antigenicity of murine skin tumors induced by ultraviolet light.

  1974cited by this paper
• ANTIGENIC PROPERTIES OF LYMPHOMAS INDUCED BY THE MOLONEY AGENT.

  1964cited by this paper
• Immunity to methylcholanthrene-induced sarcomas.

  1957cited by this paper

• Cancer-testis non-coding RNA LEF1-AS1 regulates the nuclear translocation of PDCD5 and suppresses its interaction with p53 signaling: A novel target for immunotherapy in esophageal squamous cell carcinoma.

  2023cites this paper
• Epigenetic modification of CSDE1 locus dictates immune recognition of nascent tumorigenic cells

  2023cites this paper
• Immunological and functional aspects of MAGEA3 cancer/testis antigen.

  2021cites this paper
• Flow based single cell analysis of the immune landscape distinguishes Barrett’s esophagus from adjacent normal tissue

  2019cites this paper
• Signaling lymphocytic activation molecules Slam and cancers: friends or foes?

  2018cites this paper
• Trial watch: Peptide-based vaccines in anticancer therapy

  2018cites this paper
• The dawn of vaccines for cancer prevention

  2017cites this paper
• Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses.

  2017cites this paper
• The Cellular Consequences of PASD1 Expression in Human Cancer

  2016cites this paper
• Cancer vaccines

  2015cites this paper
• Anti-viral and anti-tumor effects induced by an attenuated Marek’s disease virus in CD4- or CD8-deficient chickens

  2014cites this paper
• Tumor Mouse Model Confirms MAGE-A3 Cancer Immunotherapeutic As an Efficient Inducer of Long-Lasting Anti-Tumoral Responses

  2014cites this paper
• Telomerase activity: An attractive target for cancer therapeutics

  2014cites this paper
• Vaccination Strategies in NSCLC Patients

  2013cites this paper
• The role of telomere biology in cancer.

  2013cites this paper
• Molecular and Genetic Medicine

  2013cites this paper
• Redirected T cell activity by high affinity TCR-ANTI-CD3 bispecific candidate therapeutics

  2013cites this paper
• TumorCTL Response against the P815 the Generation of a Protective Central ALVAC Vectors Demonstrate Differences in Semliki Forest Virus, Adenovirus, and Comparative Prime-Boost Vaccinations Using

  2013cites this paper
• peptides derived from the BCR-ABL b3a2 fusion protein Direct evidence that leukemic cells present HLA-associated immunogenic

  2013cites this paper
• Cancer-testis antigens: the current status on antigen regulation and potential clinical use.

  2012cites this paper
• HORMAD2/CT46.2, a novel cancer/testis gene, is ectopically expressed in lung cancer tissues.

  2012cites this paper
• Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001

  2012cites this paper
• HORMAD 2 / CT 46 . 2 , a novel cancer / testis gene , is ectopically expressed in lung cancer tissues

  2012cites this paper
• hTERT, CD23 und CD229 als Tumorantigene bei der B-CLL

  2012influential citation
• Lung Cancer Tissues

  2012cites this paper
• Microenvironment and tumor progression of melanoma: New therapeutic prospectives

  2012cites this paper
• Cancer immunotherapy

  2012cites this paper
• transplantation for breast cancer marrow ablative chemotherapy and allogeneic bone marrow Evidence for a graft-versus-tumor effect in a patient treated with

  2011cites this paper
• NLS-dependent and insufficient nuclear localization of XAGE-1 splice variants.

  2011cites this paper
• High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer

  2011cites this paper
• Sequential Administration of the Native TERT572 Cryptic Peptide Enhances the Immune Response Initiated by its Optimized Variant TERT572Y in Cancer Patients

  2011cites this paper
• New perspectives in glioma immunotherapy.

  2011cites this paper
• Procédé pour identifier si un patient répondra ou non à une immunothérapie

  2010cites this paper
• Ograniczenia aktualnych metod leczenia raka sromu – perspektywy dla immunoterapii

  2010cites this paper
• Alternative Translational Reading Frames as a Novel Source of Epitopes for an Expanded CD8 T-Cell Repertoire: Use of a Retroviral System to Assess the Translational Requirements for CTL Recognition and Lysis

  2010cites this paper
• Viral vectors, in innate and adaptive immunity

  2009cites this paper
• Induktion von MMP-7-spezifischen, zytotoxischen T- Lymphozyten mit Hilfe dendritischer Zellen als Vorausset- zung zur Immuntherapie maligner Tumore

  2009cites this paper
• Concepts in genetic medicine

  2008cites this paper
• Prospects and challenges of building a cancer vaccine targeting telomerase.

  2008cites this paper
• Newcastle Disease Virus: A Promising Vector for Viral Therapy, Immune Therapy, and Gene Therapy of Cancer

  2008cites this paper
• Overcoming obstacles to the effective immunotherapy of human cancer

  2008cites this paper
• Peptide-Based Active Immunotherapy in Cancer

  2008cites this paper
• d'antig enes dans les Lymphomes B non Hodgkiniens

  2008cites this paper
• Predisposing Role of Immunologic determinants in the Etiology of Barrett’s Esophagus

  2008cites this paper
• Telomeres and telomerase: Biological and clinical importance in dogs.

  2008cites this paper
• Telomerase as a universal tumor antigen for cancer vaccines

  2008cites this paper
• GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers.

  2007cites this paper
• Cancer‐testis antigens in haematological malignancies

  2007influential citation
• Verfahren zur Indentifizierung des Ansprechens bzw. Nichtansprechens eines Patienten auf eine Immuntherapie basierend auf die Differentielle Expression vom Gen CD52

  2007cites this paper
• Tumor Memory CTL Response against the P 815 the Generation of a Protective Central ALVAC Vectors Demonstrate Differences in Semliki Forest Virus , Adenovirus , and Comparative Prime-Boost Vaccinations Using Benoi ?

  2007cites this paper
• Telomerase Inhibition

  2007influential citation
• Comparative Prime-Boost Vaccinations Using Semliki Forest Virus, Adenovirus, and ALVAC Vectors Demonstrate Differences in the Generation of a Protective Central Memory CTL Response against the P815 Tumor1

  2007cites this paper
• Uses of telomerase peptides in anti-tumor immune therapy.

  2007cites this paper
• Telomeres and telomerase as targets for anticancer drug development.

  2006cites this paper
• Human Ly9 (CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-CLL) recognized by autologous CD8+ T cells.

  2006cites this paper
• A central role for central tolerance.

  2006cites this paper
• Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant

  2006cites this paper
• Computational Immunology : from MHC-peptide Binding to Immunotherapy

  2006cites this paper
• Optimal organization of a polypeptide-based candidate cancer vaccine composed of cryptic tumor peptides with enhanced immunogenicity.

  2006cites this paper
• Tinkering with nature: the tale of optimizing peptide based cancer vaccines.

  2005cites this paper
• Expression of family A melanoma antigen in human gastric carcinoma.

  2005cites this paper
• Universal Breast Cancer Antigens as Targets Linking Early Detection and Therapeutic Vaccination

  2005cites this paper
• T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation

  2005cites this paper
• INDUCTION OF T-CELL RESPONSES AGAINST PSA BY

  2005cites this paper
• Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens

  2005cites this paper
• Cytological aspects of rat mammary cancer therapy with soluble tumor-associated antigens and anticancer drugs.

  2005cites this paper
• Barrett's oesophagus is characterized by a predominantly humoral inflammatory response

  2005cites this paper
• Cancer vaccines

  2005cites this paper
• Cancer/testis antigens, gametogenesis and cancer

  2005cites this paper
• Induction of t-cell responses against PSA by plasmid DNA immunization

  2005cites this paper
• CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes.

  2005cites this paper
• Direct intralymphatic injection of peptide vaccines enhances immunogenicity

  2005cites this paper
• Influence of flanking sequences on presentation efficiency of a CD8+ cytotoxic T-cell epitope delivered by parvovirus-like particles.

  2004cites this paper
• Self-Reactive T Cell Receptor-Reactive CD8+ T Cells Inhibit T Cell Lymphoma Growth In Vivo1

  2004cites this paper
• WT1 is a tumor‐associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells

  2004cites this paper
• Induktion von c-Met-spezifischen zytotoxischen T-Lymphozyten mit Hilfe dendritischer Zellen als Voraussetzung für einen späteren Einsatz in der Immuntherapie maligner Tumoren

  2004cites this paper
• High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

  2004cites this paper
• Anti-tumour effect in solid tumours, tolerance and immune reconstition after allogeneic haematopoietic stem cell transplantation

  2004cites this paper
• Telomerase as a tumor-associated antigen for cancer immunotherapy

  2004influential citation
• Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens

  2004cites this paper
• Chapter 58 – Are Vaccinations for Prostate Cancer Realistic?

  2003cites this paper
• Principles of Cancer Immunotherapy

  2003cites this paper
• Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors

  2003cites this paper
• The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation.

  2003cites this paper
• Immunodeficiency and cancer: prospects for correction.

  2003cites this paper
• A Human Minor Histocompatibility Antigen Resulting from Differential Expression due to a Gene Deletion

  2003cites this paper
• Recombinant adenylate cyclase toxin of Bordetella pertussis induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes.

  2003cites this paper
• Dendritic Cells and their Potential Therapeutic Role in Haematological Malignancy

  2003cites this paper
• Immunoglobulin repertoire of B lymphocytes infiltrating breast medullary carcinoma

  2003cites this paper
• Frequenzanalyse und Charakterisierung Antigen-spezifischer T-Zellen bei Melanompatienten unter Immuntherapie

  2003cites this paper
• Targeting Adult and Pediatric Cancers via Cell-Based Vaccines and the Prospect of Activated B Lymphocytes as a Novel Modality

  2003cites this paper
• Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen.

  2003cites this paper
• T-cell therapy of leukemia.

  2002cites this paper
• High-Affinity HLA-A(*)02.01 Peptides from Parathyroid Hormone-Related Protein Generate In Vitro and In Vivo Antitumor CTL Response Without Autoimmune Side Effects1

  2002cites this paper
• Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects.

  2002cites this paper
• Effects CTL Response Without Autoimmune Side Generate In Vitro and In Vivo Antitumor Parathyroid Hormone-Related Protein High-Affinity HLA-A ( * ) 02 . 01 Peptides from Pierpaolo Correale

  2002cites this paper
• The Immunobiology of Malignant Melanoma

  2002cites this paper
• Contribution of LCMV transgenic models to understanding T lymphocyte development, activation, tolerance, and autoimmunity.

  2002cites this paper
• A scFv Phage Display Mini Library Generated from the Immunoglobulin Repertoire of Breast Medullary Carcinoma Infiltrating B Lymphocytes

  2002cites this paper
• Cancer/Testis Antigens: Structural and Immunobiological Properties

  2002cites this paper